Toxicant single-species risk prediction

In single-species risk prediction for individual toxicants and toxicant mixtures, the effect is expressed as the proportion of an exposed population that is likely to be somehow affected by toxic action (quantal responses), or as a reduction in performance parameters such as growth, clutch size, and juvenile period (continuous responses). Both concentration addition- and response addition-based methods are commonly applied for both response types. Assemblage-level risk prediction has only been introduced more recently (e.g., De Zwart and Posthuma 2005) and is founded on similar principles while focusing on the fraction of species that are likely affected by mixture exposure. 

Recently, some models have been derived to analyze the occurrence of interactive joint action in binary single-species toxicity experiments (Jonker 2003). Such detailed analysis models are well equipped to serve as null models for a precision analysis of experimental data, next to the generalized use of concentration addition and response addition as alternative null models. However, in our opinion these models are not applicable to quantitatively predict the combined toxicity of mixtures with a complexity that is prevalent in a contaminated environment, because the parameters of such models are typically not known. Recently a hazard index (Hertzberg and Teus-chler 2002) was developed for human risk assessment for exposure to multiple chemicals. Based on a weight-of-evidence approach, this index can be equipped with an option to adjust the index value for possible interactions between toxicants. It seems plausible that a comparable kind of technique could be applied in ecotoxicological risk assessments of mixtures for single species. However, at present, the widespread application of this approach is prevented by lack of available information. 

Animal tests in a single species do not always predict human toxicities but when these tests are carried out in several species, most acute toxicities that occur in humans will also appear in at least one animal species. According to current FDA rules, the degree of risk must be determined in at least two species. Use of primates is not always required. The therapeutic index is not required. Except for cancer chemotherapeutic agents, phase I clinical trials are always carried out in normal subjects. The answer is (B). 

---